Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Theravance Biopharma, Inc.NASDAQ: TBPH

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $4.5M fell 7.6% year over year, ahead of the -14.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at -22.5% a year.

Context

  • Stock-based compensation amounted to 17.2% of revenue in FY2025, down 16.0 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -7.6% holds above the trailing-twelve-month pace of -14.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.5M+0.5% QoQ
Last fiscal yearDec 2025
$18.48M-13.6% YoY
LTMMar 2026
$18.1M-14.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.6%——
1 year-13.6%——
3-year CAGR-22.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
18.48M USD
Year-over-year change
-13.6%
4-year CAGR
-26.1%

Stock-Based Compensation vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -14.0% is the 7th highest of 8, against a peer median of +17.1%.
  • Stock-based compensation amounts to 16.5% of revenue for TBPH, versus a peer median of 45.4%.
TBPH Competitors
Stock-Based Compensation for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$35.01M USD+17.1%-21.7%53.5%
REPLReplimune Group, Inc.LTM Dec 2025$32.43M USD-6.5%+13.1%—
TYRATyra Biosciences, Inc.LTM Mar 2026$29.43M USD+17.2%+38.3%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$19.52M USD+5.2%+17.4%45.4%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$18.1M USD-14.0%-22.5%16.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$15.73M USD+224.1%+209.1%—
GERNGeron CorporationLTM Mar 2026$11.73M USD-65.3%-77.8%6.0%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$9.99M USD+25.3%—47.6%
VALNValneva SELTM Mar 2026€0 EUR——0.0%
Peer median (excluding TBPH) —+17.1%+15.2%45.4%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265.07M)(92.82M)(55.19M)(56.42M)105.9M
Depreciation & Amortization8.6M7.02M4.26M3.62M5.64M
Deferred Income Tax003.21M(7.57M)(11.52M)
Stock-Based Compensation62.06M39.73M25.37M21.39M18.48M
Change in Working Capital(39.55M)42.35M(8.34M)20.36M120.47M
Accounts Receivables1.8M(2.72M)(689K)(966K)(27.1M)
Inventory00000
Accounts Payables(3.53M)(1.61M)6K750K326K
Other Working Capital(37.82M)46.68M(7.66M)20.57M147.24M
Other Non-Cash Items26.1M(183.28M)3.7M7.09M(423K)
Operating Cash Flow(207.86M)(186.99M)(27M)(11.54M)238.54M
Capital Expenditures(3.41M)(572K)(2.49M)(332K)(42K)
Acquisitions (Net)00000
Purchases of Investments(158.31M)(103.15M)(134.53M)(143.04M)(248.22M)
Sales of Investments286.2M158.02M102.81M155.65M142.98M
Other Investing Activities6K1.1B1.51M00
Investing Cash Flow124.49M1.15B(32.7M)12.28M(105.28M)
Debt Repayment(10.73M)(631.6M)000
Common Stock Issued108.18M0099K786K
Common Stock Repurchased(9.06M)(132.28M)(199.55M)(3.1M)(4.03M)
Dividends Paid00000
Other Financing Activities3.47M5.08M618K508K0
Financing Cash Flow91.86M(758.81M)(198.93M)(2.5M)(3.25M)
Effect of Forex Changes00000
Net Change in Cash8.5M208.21M(258.63M)(1.75M)130.01M
Free Cash Flow(211.26M)(187.56M)(29.49M)(11.87M)238.5M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.